News for Voyager Therapeutics, Inc. (VYGR.MX)

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ETCompany ParticipantsTrista Morrison - Chief Corporate...

**media[563711]**

LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. ( VYGR), a biotechnology company dedicated to advancing neurogenetic medicines

PR NewswireNEW YORK, March 3, 2025 NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeu

- Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profil

PR NewswireNEW YORK, Feb. 25, 2025 NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeu

LEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. ( VYGR), a biotechnology company dedicated to advancing neurogenetic medicines,

PR NewswireLOS ANGELES, Feb. 21, 2025 LOS ANGELES, Feb. 21, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announ

PR NewswireNEW YORK, Feb. 18, 2025 NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therape

On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio), a notable investment firm, executed a significant transaction by acquiring an additional 196,0

**media[537489]**

PR NewswireSAN DIEGO, Feb. 6, 2025 INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Represent

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's results. Click for this VYGR update.

On January 14, 2025, Robin Swartz, Chief Operating Officer & Chief Business Officer at Voyager Therapeutics Inc, sold 3,087 shares of the company. Following thi

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where Voyager Therapeutics, Inc. (NASDAQ:VYGR) stands against the other...

Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.

On December 23, 2024, Robin Swartz, Chief Operating Officer and Chief Business Officer of Voyager Therapeutics Inc, sold 6,500 shares of the company, as reporte

**media[471359]**

- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro